Advertisement

Drug Safety

, Volume 37, Issue 8, pp 629–637 | Cite as

Undesirable Effects Related to Oral Antineoplastic Drugs: Comparison Between Patients’ Internet Narratives and a National Pharmacovigilance Database

  • Arnaud Pages
  • Emmanuelle Bondon-Guitton
  • Jean Louis Montastruc
  • Haleh Bagheri
Original Research Article

Abstract

Background

The Internet is changing the way people learn about health and illness. Over the previous decade, the oral antineoplastic (OAN) agents have changed patient management allowing more ambulatory care. In this regard, websites could be an interesting source of data about OAN-induced adverse events (AEs).

Objective

The aim of the study was to describe the characteristics of AEs, as reported on websites by patients exposed to OAN agents, and to compare these to those recorded in the French pharmacovigilance database (FPVD).

Methods

We performed a retrospective study to collect AEs reported by patients in five of the best-known website forums in France over 1 year (2011). For each report, we recorded demographic data, cancer type, drug involved and AEs. The same analysis was done in the FPVD for OAN-induced adverse drug reactions (ADRs).

Results

A total of 202 AEs were identified in website posts and 1,448 ADRs were found in the FPVD. The most cited drugs in websites were protein kinase inhibitors (n = 88, 43.5 %) and hormone antagonists (n = 61, 30.2 %). More musculoskeletal disorder reports were found in the patient websites compared with the FPVD (16.34 vs. 4.70 %, p < 0.001). As for skin disorders, we collected fewer reports in the patient website forums than in the FPVD (13.37 vs. 22.17 %, p = 0.004). AEs reported in the patient websites were less serious (n = 10, 4.95 %) than ADRs recorded in the FPVD (n = 999, 68.99 %) (p < 0.001).

Conclusions

AEs reported in the website forums are considered by patients to be relevant enough to be shared. Data from patient websites could be used as a source of data to detect AEs alongside conventional pharmacovigilance.

Keywords

Sunitinib Letrozole Dasatinib Anastrozole Nilotinib 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Funding

No sources of funding were used to assist in the preparation of this study.

Conflict of interest

Arnaud pages, Emmanuelle Bondon-Guitton, Jean Louis Montastruc and Haleh Bagheri have no conflicts of interest that are directly relevant to the content of this study.

Supplementary material

40264_2014_203_MOESM1_ESM.pdf (139 kb)
Supplementary material 1 (PDF 138 kb)
40264_2014_203_MOESM2_ESM.pdf (138 kb)
Supplementary material 2 (PDF 137 kb)

References

  1. 1.
    Bartlett YK, Coulson NS. An investigation into the empowerment effects of using online support groups and how this affects health professional/patient communication. Patient Educ Couns. 2011;83:113–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Armstrong N, Powell J. Patient perspectives on health advice posted on Internet discussion boards: a qualitative study. Health Expect. 2009;12:313–20.PubMedCrossRefGoogle Scholar
  3. 3.
    Lee C, Gray SW, Lewis N. Internet use leads cancer patients to be active health care consumers. Patient Educ Couns. 2010;81:S63–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Fox S. The social life of health information. Pew Internet, Pew Research Center. 2011. Available: http://www.pewinternet.org/Reports/2011/Social-Life-of-Health-Info.aspx.
  5. 5.
    Schröder S, Zöllner YF, Schaefer M. Drug related problems with antiparkinsonian agents: consumer Internet reports versus published data. Pharmacoepidemio Drug Saf. 2007;16:1161–6.CrossRefGoogle Scholar
  6. 6.
    Moncrieff J, Cohen D, Mason JP. The subjective experience of taking antipsychotic medication: a content analysis of Internet data. Acta Psychiatr Scand. 2009;120:102–11.PubMedCrossRefGoogle Scholar
  7. 7.
    Wicks P, Massagli M, Frost J, et al. Sharing health data for better outcomes on PatientsLikeMe. J Med Internet Res. 2010;12:e19.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Posts about drugs, side effects, conditions and symptoms: Treato. Available at: http://treato.com/. Accessed 10 January 2013.
  9. 9.
    Chee BW, Berlin R, Schatz B. Predicting adverse drug events from personal health messages. AMIA Annu Symp Proc. 2011;2011:217–26.PubMedCentralPubMedGoogle Scholar
  10. 10.
    Schultz P, Stava C, Beck M, et al. Internet message board use by patients with cancer and their families. Clin J Oncol Nurs. 2003;7:663–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Nagler RH, Gray SW, Romantan A, et al. Differences in information seeking among breast, prostate, and colorectal cancer patients: results from a population-based survey. Patient Educ Couns. 2010;81:S54–62.PubMedCrossRefGoogle Scholar
  12. 12.
    Mao JJ, Chung A, Benton A, et al. Online discussion of drug side effects and discontinuation among breast cancer survivors. Pharmacoepidemiol Drug Saf. 2013;22:256–62.PubMedCrossRefGoogle Scholar
  13. 13.
    Benton A, Ungar L, Hill S, et al. Identifying potential adverse effects using the web: a new approach to medical hypothesis generation. J Biomed Inform. 2011;44:989–96.PubMedGoogle Scholar
  14. 14.
    Bordonaro S, Raiti F, Di Mari A, et al. Active home-based cancer treatment. J Multidiscip Healthc. 2012;5:137–43.PubMedCentralPubMedGoogle Scholar
  15. 15.
    Faye E, Bondon-Guitton E, Olivier-Abbal P, Montastruc JL. Spontaneous reporting of serious cutaneous reactions with protein kinase inhibitors. Eur J Clin Pharmacol. 2013;69:1819–26.PubMedCrossRefGoogle Scholar
  16. 16.
    Haramburu F, Miremont-Salamé G, Bénard A, et al. Incidence of hospital admissions due to adverse drug reactions: the EMIR study. Fundam Clin Pharmacol. 2008;22(Suppl 1):20.Google Scholar
  17. 17.
    Le top 5 des sites de santé français: JDN Web & Tech. Available at: http://www.journaldunet.com/ebusiness/le-net/audience-sites-sante/. Accessed 5 June 2012.
  18. 18.
    Bégaud B, Evreux JC, Jouglard J, et al. Imputation of the unexpected or toxic effects of drugs: actualization of the method used in France. Therapie. 1985;40:111–8.PubMedGoogle Scholar
  19. 19.
    ATC/DDD Index 2013 (n.d.). Available at: http://www.whocc.no/atc_ddd_index/. Accessed 11 August 2012.
  20. 20.
    Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20:109–17.PubMedCrossRefGoogle Scholar
  21. 21.
    Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–74.PubMedCrossRefGoogle Scholar
  22. 22.
    Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356:1255–9.PubMedCrossRefGoogle Scholar
  23. 23.
    European Medicines Agency. Available at: http://www.ema.europa.eu/ema/. Accessed 29 August 2012.
  24. 24.
    Moore N, Noblet C, Kreft-Jais C, et al. French pharmacovigilance database system: examples of utilisation. Therapie. 1995;50:557–62.PubMedGoogle Scholar
  25. 25.
    Buetow S, Henshaw J, Cha R, et al. Distinguishing objective from subjective assessments of the severity of medication-related safety events among people with Parkinson’s disease: a qualitative study. J Clin Pharm Ther. 2012;37:436–40.PubMedCrossRefGoogle Scholar
  26. 26.
    Somers A, Petrovic M, Robays H, et al. Reporting adverse drug reactions on a geriatric ward: a pilot project. Eur J Clin Pharmacol. 2003;58:707–14.PubMedGoogle Scholar
  27. 27.
    Sacilotto K, Bagheri H, Lapeyre-Mestre M, et al. Adverse drug effects notifications by nurses and comparison with cases reported by physicians. Therapie. 1995;50:455–8.PubMedGoogle Scholar
  28. 28.
    Amitay-Laish I, Stemmer SM, Lacouture ME. Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib. Dermatol Ther. 2011;24:386–95.PubMedCrossRefGoogle Scholar
  29. 29.
    Burstein HJ, Winer EP. Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors. J Clin Oncol. 2007;25:3797–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Fontein DBY, Nortier JWR, Liefers GJ, et al. High non-compliance in the use of letrozole after 2.5 years of extended adjuvant endocrine therapy: results from the IDEAL randomized trial. Eur J Surg Oncol. 2012;38:110–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Hughes S, Cohen D. Can online consumers contribute to drug knowledge? A mixed methods comparison of consumer-generated and professionally controlled psychotropic medication information on the internet. J Med Internet Res. 2011;13:e53.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Hazell L, Cornelius V, Hannaford P, et al. How do patients contribute to signal detection? A retrospective analysis of spontaneous reporting of adverse drug reactions in the UK’s Yellow Card Scheme. Drug Saf. 2013;36:199–206.PubMedCrossRefGoogle Scholar
  33. 33.
    Blenkinsopp A, Wilkie P, Wang M, et al. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol. 2007;63:148–56.PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    MBongue TB, Sommet A, Pathak A. “Medicamentation” of society, non-disease and non-medications: a point of view from social pharmacology. Eur J Clin Pharmacol. 2005;61:309–13.PubMedCrossRefGoogle Scholar
  35. 35.
    Aboutaam M. Analysis of patients’ narratives posted on social media websites on benfluorex (Mediator®) withdrawal in France. J Clin Pharm Ther. 2014;39:53–5.CrossRefGoogle Scholar
  36. 36.
    Jarernsiripornkul N, Krska J, Capps PA, et al. Patient reporting of potential adverse drug reactions: a methodological study. Br J Clin Pharmacol. 2002;53:318–25.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  • Arnaud Pages
    • 1
  • Emmanuelle Bondon-Guitton
    • 1
  • Jean Louis Montastruc
    • 1
  • Haleh Bagheri
    • 1
  1. 1.Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d’Informations sur le Médicament, INSERM U1027, Faculté de MédecineCHU de Toulouse, Université de ToulouseToulouseFrance

Personalised recommendations